An observational study in GH Deficiency, sponsored by Istituto Auxologico Italiano. Completed at 1 site in Italy. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Istituto Auxologico Italiano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Dwarfism, Pituitary with a site in Italy — 2 open to participants now, 2 under way, none of them phase 3. Dwarfism, Pituitary · Italy.
Among the 28 studies in Dwarfism, Pituitary with a site in Italy, this one is the only one that started in 2022, is one of 8 observational ones, and was the 25th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →2 of the 28 studies in Dwarfism, Pituitary with a site in Italy are open now. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 5–18
University of Parma · Sites in Italy
Ages 2–15
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 5 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 70 across 73 observational studies indexed under Dwarfism, Pituitary.
Median enrollment 83 across the 19 interventional studies, 38 across the 8 observational. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Istituto Auxologico Italiano has 2 studies filed under Dwarfism, Pituitary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Dwarfism, Pituitary with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the size and derivational profile of the extracellular vescicles (EV) generated in children with GH deficiency, undergoing hormone replacement therapy with rhGH. Secondary objectives is to correlate vesiculogenesis with auxometric and biochemical parameters used in clinical-endocrine practice in the evaluation of short stature.
The results of the study will provide useful information to more rationally set up the clinical and biochemical follow-up of hormone replacement therapy with rhGH, as well as to understand the molecular and cellular mechanisms underlying the multi-systemic action of GH, the most important anabolic hormone of the human organism.
Methods:
At the Regional Reference Center for Growth Disorders, Istituto Auxologico Italiano, IRCCS, Milan, 10 children of both sexes affected by isolated GH deficiency will be recruited according to the criteria set out in AIFA note 39 for this pathology (short stature: ≤ - 3 SD or ≤ -2 SD and growth velocity/year ≤ -1.0 SD for age and sex evaluated at least 6 months apart and peak GH at two different stimulating pharmacological tests \< 8 ng/ml). The exclusion criterion from the present study (and from treatment with rhGH) will be the presence of organic pathologies at the hypothalamic-pituitary level (assessed by brain MRI).
In basal conditions (pre-treatment), we will proceed with the collection of clinical and anthropometric/auxometric data, including the evaluation of body composition with bioimpedance analysis. The same work-up will be repeated at the subsequent 6-month follow-up (see below).
Each subject will undergo hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
In conditions of fasting (at least 12 hours), blood samples will be taken at T0 (i.e., before the start of hormone replacement therapy with rhGH) and at T6 (i.e., after 6 months of rhGH, approximately 10-12 hours after administration of the previous day's dose).
In the samples taken at T0 and T6, the dimensional and derivational profiles of the EVs will be determined. Markers for the following cell subtypes will be identified: endothelium (activated and not), monocytes, neutrophils, platelets, muscle, bone, and adipose tissue.
In basal conditions (T0) and at T6 the patients will be sampled for the determination of the following parameters: complete blood count + formula, blood glucose, insulin, glycated Hb, triglycerides, total cholesterol, LDL, HDL, hsPCR, IGF-1, osteocalcin, ICTP, and PIIIINP.
Quantitative data will be expressed as mean ± SD or as median with interquartile range (Q1-Q3), as appropriate. Categorical data will be presented as frequencies and percentages, while continuous variables will be tested for normality and linearity. If appropriate, a log transformation of the data will be performed. The paired Student's t-test (or other non-parametric test) will be used to compare demographic, clinical, and biochemical characteristics among the same subjects at T0 vs. T6. EVs will be subdivided according to their size (exosomes, microvesicles, and total EVs) and their cellular origin identified by specific markers (e.g., CD14+, CD61+, CD62E+, CD105+, SCGA+, FABP+, etc). Multiple linear regression analysis will be applied to evaluate the association between EVs (as Δ% between T0 and T6 for the dimensional and also derivational profile), circulating IGF-1 levels (as Δ% between T0 and T6), and the rate of growth (T0 to T6). In addition, a paired Student t-test will be used to assess the rhGH-induced change in EV (T0 vs. T6). The test will be applied for all EV populations studied with the size profile and for all vesicular markers studied with the derivational profile. Alternatively, a non-parametric test will be applied. A p-value \< 0.05 will be considered.
10 children of both sexes affected by isolated GH deficiency will be recruited according to the criteria set out in AIFA note 39 for this pathology (short stature: ≤ - 3 SD or ≤ -2 SD and growth velocity/year ≤ -1.0 SD for age and sex evaluated at least 6 months apart and peak GH at two different stimulus pharmacological tests \< 8 ng/ml).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- presence of organic pathologies at the hypothalamic-pituitary level (assessed by performing brain MRI).
Drug: rhGH
Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
Size of extracellular vesicles
Change in size of extracellular vesicles after rhGH treatment
Time frame: Baseline and after 6 months
Derivational profile of extracellular vesicles
Change in derivational profile of extracellular vesicles after rhGH treatment
Time frame: Baseline and after 6 months
Auxometric parameters - height
Change in height after rhGH treatment
Time frame: Baseline and after 6 months
Auxometric parameters - weight
Change in weight after rhGH treatment
Time frame: Baseline and after 6 months
Biochemical parameters - glycemia
Change in glycemia after rhGH treatment
Time frame: Baseline and after 6 months
Biochemical parameters - Insulin-like growth factor I (IGF-I)
Change in IGF-I after rhGH treatment
Time frame: Baseline and after 6 months
Ran from Jun 2022 to primary completion in Mar 2026, 45 months.
Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's 45 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2025 → Mar 2026 and completion Dec 2025 → Mar 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →